Browse by category

Researchers have found that people regain weight faster after quitting these GLP-1s compared with after diet and exercise alone. Improvements in heart health and diabetes risk also tend to reverse within a few years. The results suggest long-term success may require more than medication alone. The findings call into question how durable these treatments really are. On average, individuals regained about 0.4 kilograms per month after stopping medication. Based on these trends

Higher rates of death among younger Australians from cardiovascular disease has been linked to being overweight or obese, a study by researchers at the University of Melbourne has reported. The study looked at premature overweight and obesity-related cardiovascular disease mortality for people aged between 35–74 years. Professor Tim Adair, a demographer in the Nossal Institute for Global Health at the University of Melbourne, used Australian Bureau of Statistics death certifi

Both biliopancreatic diversion with duodenal switch (BPD/DS) or single anastomosis duodeno-ileal bypass with sleeve gastrectomy (SADI-S) show comparable short-term outcomes when performed as revisional procedures following RYGB. Although overall perioperative complications did not differ between groups, the approximately 6% anastomotic leak rate observed in both cohorts highlights the greater complexity and risk inherent to revisional bariatric surgery relative to primary ope

Genentech announced positive topline results from CT388-103, a Phase II clinical trial of CT-388, an investigational dual GLP-1/GIP receptor agonist being developed for the treatment of obesity. The study found that once-weekly subcutaneous injections of CT-388 (titrated up to 24 mg) resulted in significant and clinically meaningful placebo-adjusted weight loss of 22.5% (efficacy estimand) without reaching a weight loss plateau at 48 weeks. CT-388 aims to reduce appetite and

Ring-augmented sleeve gastrectomy (Ra-SG) achieved statistically greater weight-loss durability at 36 months compared with standard sleeve gastrectomy (SG), according to the outcomes from a randomised clinical trial by researchers from Egypt. They also reported that Ra-SG has a lower incidence of clinically significant RWG and smaller gastric pouch volumes at three years. According to the authors, although Ra-SG has the potential to improve SG by placing a non-adjustable ring

The first participants have been dosed in Ascletis Pharma’s US 13-week Phase II study with ASC30, an oral small molecule GLP-1 receptor (GLP-1R) agonist for the treatment of type 2 diabetes mellitus. Topline data from the Phase II study are expected in the third quarter of 2026. Ascletis recently completed a 13-week Phase II study evaluating ASC30 for the treatment of obesity in 125 participants with obesity or overweight with at least one weight-related comorbidity at multip